Alignment Healthcare (ALHC) could be a solid addition to your portfolio given its recent upgrade to a Zacks Rank #2 (Buy). This rating change essentially reflects an upward trend in earnings estimates -- one of the most powerful forces impacting stock prices.A company's changing earnings picture is at the core of the Zacks rating. The system tracks the Zacks Consensus Estimate -- the consensus measure of EPS estimates from the sell-side analysts covering the stock -- for the current and following years.The ...

For more than 10 years, Alignment has harnessed trusted artificial intelligence (AI) through AVA – the company's proprietary Medicare Advantage platform – to drive actionable clinical insights that improve senior health outcomes and quality of care. Dr. Bakshandeh's appointment reinforces Alignment's commitment to scaling the platform and further integrating data-driven solutions into every step of the member journey. Using 200+ data sources and 13,000+ attributes to generate secure and personalized insight ...

Group 1 - Alignment Healthcare, Inc. (NASDAQ:ALHC) will release its first quarter 2025 financial results on May 1, 2025, after market close [1] - A conference call to review the financial results will take place at 5 p.m. EDT on the same day [1] - A live audio webcast of the conference call will be available online, with a replay accessible for approximately 12 months [2] Group 2 - Alignment Health focuses on empowering seniors to age well and live vibrant lives through high-quality, low-cost care for Medicare Advantage members [3] - The company partners with trusted local providers to deliver coordinated care, utilizing its customized care model and technology, AVA® [3] - Alignment Health emphasizes its core values of serving the senior community and expanding its national footprint [3]

Alignment Healthcare (ALHC) shares rallied 6.3% in the last trading session to close at $18.95. This move can be attributable to notable volume with a higher number of shares being traded than in a typical session. This compares to the stock's 18.6% gain over the past four weeks.Alignment Healthcare scored a strong price increase, on investors’ optimism driven by reports of Stifel increasing the company’s price target to $23 from $18 with a Buy rating. The development came after Centers for Medicare & Medic ...

Agreement brings continued access to high-quality care for Alignment’s Medicare Advantage members ORANGE, Calif., March 18, 2025 (GLOBE NEWSWIRE) -- Sutter Health and Alignment Healthcare, Inc. (NASDAQ: ALHC) have renewed their agreement that provides Alignment Healthcare members with continued in-network access to Sutter’s integrated network of high-quality, comprehensive care in Northern California. This agreement applies to Alignment Healthcare members enrolled in Sutter Advantage HMO and My Choice PPO h ...

Alignment Healthcare, Inc. (NASDAQ:ALHC) Q4 2024 Results Conference Call February 27, 2025 5:00 PM ET Company Participants John Kao - Founder & Chief Executive Officer Thomas Freeman - Chief Financial Officer Conference Call Participants Scott Fidel - Stephens Adam Ron - Bank of America Michael Ha - Baird Matthew Gillmor - KeyBanc Capital Markets Jessica Tassan - Piper Sandler Operator Good afternoon, and welcome to Alignment Healthcare's Fourth Quarter 2024 Earnings Conference Call and Webcast. [Operator I ...

ORANGE, Calif., Feb. 28, 2025 (GLOBE NEWSWIRE) -- Alignment Healthcare, Inc. (NASDAQ: ALHC), today announced that it will present at the following conferences: Leerink Global Healthcare Conference on Tuesday, March 11, at 3:40 p.m. EDTKeyBanc Capital Markets Healthcare Forum on Wednesday, March 19, at 10:30 a.m. EDT A webcast and replay of the presentations will be available on Alignment’s investor relations website at https://ir.alignmenthealth.com/. About Alignment HealthcareAlignment Health is championin ...

Core Insights - Alignment Healthcare (ALHC) reported a revenue of $701.24 million for Q4 2024, marking a year-over-year increase of 50.7% [1] - The company's EPS for the same period was -$0.16, an improvement from -$0.25 a year ago [1] - The reported revenue exceeded the Zacks Consensus Estimate of $677.04 million by 3.58%, and the EPS also surpassed the consensus estimate of -$0.18 by 11.11% [1] Financial Performance Metrics - Medical Benefit Ratio was reported at 87.5%, better than the five-analyst average estimate of 89.4% [4] - Health Plan Membership at the end of the quarter was 189,100, exceeding the average estimate of 185,005 from four analysts [4] - Revenues from Other sources were $9.46 million, surpassing the estimated $7.48 million, reflecting a 48.3% increase compared to the previous year [4] - Earned Premiums revenue was $691.79 million, compared to the estimated $668.26 million, also showing a 50.7% increase year-over-year [4] Stock Performance - Over the past month, shares of Alignment Healthcare have declined by 14.1%, while the Zacks S&P 500 composite decreased by 2.2% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Company Performance - Alignment Healthcare reported a quarterly loss of $0.16 per share, better than the Zacks Consensus Estimate of a loss of $0.18, and an improvement from a loss of $0.25 per share a year ago, representing an earnings surprise of 11.11% [1] - The company posted revenues of $701.24 million for the quarter ended December 2024, exceeding the Zacks Consensus Estimate by 3.58%, and showing significant growth from year-ago revenues of $465.39 million [2] - Over the last four quarters, Alignment Healthcare has surpassed consensus EPS estimates two times and topped consensus revenue estimates four times [2] Stock Outlook - The immediate price movement of Alignment Healthcare's stock will largely depend on management's commentary during the earnings call and future earnings expectations [3] - The stock has gained approximately 17% since the beginning of the year, outperforming the S&P 500's gain of 1.3% [3] Earnings Estimates - The current consensus EPS estimate for the upcoming quarter is -$0.20 on revenues of $848.58 million, and for the current fiscal year, it is -$0.47 on revenues of $3.44 billion [7] - The estimate revisions trend for Alignment Healthcare is currently unfavorable, resulting in a Zacks Rank 4 (Sell) for the stock, indicating expected underperformance in the near future [6] Industry Context - The Medical Services industry, to which Alignment Healthcare belongs, is currently ranked in the top 34% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8]

Financial Performance - The company reported a net loss, highlighting challenges in achieving profitability amid increasing expenses[12]. - The net loss attributable to Alignment Healthcare, Inc. for 2024 was $128.0 million, compared to a net loss of $148.0 million in 2023, indicating a 13.5% improvement[458]. - The net loss for 2024 was $128,071, a reduction from a net loss of $148,173 in 2023, indicating an improvement in financial performance[473]. - The total stockholders' equity decreased to $100.9 million in 2024 from $158.1 million in 2023, a decline of 36.2%[456]. - The company recorded a net income tax expense of $21 for the year ended December 31, 2024, compared to a benefit of $(22) in 2023[564]. - The equity in loss of subsidiary was $125,892 in 2024, compared to $147,529 in 2023, showing a decrease in losses from subsidiaries[616]. Revenue and Expenses - Total revenues for the year ended December 31, 2024, were $2,703.6 million, representing a 48.3% increase from $1,823.6 million in 2023[458]. - Medical expenses for 2024 amounted to $2,406.9 million, up 48.2% from $1,622.6 million in 2023[458]. - Premium revenue for 2024 was $2,666,813, a substantial increase from $1,668,131 in 2023, demonstrating strong growth in the Medicare Advantage sector[476]. - Capitation revenue for 2024 was $5,118, a decrease from $132,802 in 2023, indicating a shift in revenue sources[476]. - The total incurred medical expenses for the current year reached $832,819 million in 2024, significantly higher than the $492,315 million incurred in 2023[551]. - Medical expenses payable rose to $289.8 million in 2024, up 40.9% from $205.4 million in 2023[456]. Assets and Liabilities - Total current assets increased to $661.6 million in 2024 from $483.5 million in 2023, reflecting a growth of 36.8%[456]. - The company's total assets reached $782.1 million as of December 31, 2024, compared to $591.9 million in 2023, marking a 32.2% increase[456]. - Long-term debt increased significantly to $321.4 million in 2024 from $161.8 million in 2023, representing a 98.7% rise[456]. - The total liabilities rose to $325,182 in 2024 from $1,319 in 2023, reflecting a substantial increase due to new debt issuance[612]. - Cash and cash equivalents at the end of 2024 were $432,859, compared to $204,904 at the end of 2023, reflecting a significant increase in liquidity[465]. Investments and Financial Instruments - As of December 31, 2024, the company held $71.1 million in U.S. Treasury bills classified as held to maturity[436]. - The carrying value of U.S. Treasury bills decreased from $117,337 million in 2023 to $71,120 million in 2024, reflecting a significant reduction in investments[538]. - The company had $469,373 million in excess of FDIC-insured limits as of December 31, 2024, compared to $316,977 million in 2023, indicating increased cash reserves[520]. - As of December 31, 2024, the company had restricted investments in U.S. Treasury bills amounting to $1,033 million and certificates of deposits totaling $2,321 million[542]. Operational Efficiency and Management - The company is focused on maintaining high ratings on the Five Star Quality Rating System to enhance its competitive position[12]. - The company entered into a management services and risk management agreement with a third-party healthcare company in 2024, which is expected to enhance operational efficiency[481]. - The company’s management team has limited experience managing a public company, which may impact future performance[12]. Regulatory and Compliance - Medicare Advantage Plans in California, North Carolina, Nevada, Arizona, Texas, and Florida are subject to a minimum annual medical loss ratio (MLR) of 85%[486]. - The company is required to remit a portion of premiums back to the federal government if the minimum MLR is not met, although amounts payable were immaterial as of December 31, 2024[486]. - The Inflation Reduction Act is expected to have an immaterial impact on the company's consolidated financial statements at December 31, 2024, with provisions set to take effect over the next seven years[511]. Shareholder and Equity Information - The weighted-average common shares outstanding increased to 190.8 million in 2024 from 186.2 million in 2023, an increase of 2.8%[458]. - As of December 31, 2024, there were 8,762,481 stock options outstanding with a weighted-average exercise price of $16.97[571]. - The company granted 6,994,001 restricted stock units (RSUs) in 2024, with unvested and outstanding RSUs totaling 13,344,685 at year-end[575]. - Total equity-based compensation expense was $71,132, an increase from $66,835 in 2023[580]. Legal and Contingent Liabilities - The company accrued a potential liability of $913 related to a class action lawsuit as of December 31, 2024[599].